UbiVac LLC is developing a new cancer vaccine technology based on hormones and enzymes produced by tumor cells. UbiVac is a development stage biotechnology company that is focused on discovering, licensing, improving and commercializing immunotherapy products that safely generate and augment the immune response to vaccines. Preclinical studies document that UbiVac technology is significantly more effective than current âgold standard vaccines at inducing tumor regression and increasing survival of tumor-bearing hosts. Based on these data a phase I clinical trial of UbiVac vaccine technology will be initiated in patients with non-small cell lung cancer (NSCLC) in the first quarter of 2008. UbiVac is also exploring the application of this approach to the development of an avain flu vaccine
